Application of SC technologies in clinical trials. Parallel analysis of mutant HSPCs to assess the response to novel therapies and correlate with disease outcomes. HSPCs, hematopoietic stem and progenitor cells; HSPC CMR, complete molecular response (no mutation detected in HSPC compartment); HSPC PMR, partial molecular response (mutation reduction >50% in HSPC compartment); No HSPC MR, no molecular response (no mutation reduction in HSPC compartment); SC, single-cell.